| Literature DB >> 15963273 |
Simona Bratu1, Antonella Eramo, Robert Kopec, Elizabeth Coughlin, Monica Ghitan, Robert Yost, Edward K Chapnick, David Landman, John Quale.
Abstract
Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) has rarely been reported in the hospital setting. We report an outbreak of 7 cases of skin and soft tissue infections due to a strain of CA-MRSA. All patients were admitted to the labor and delivery, nursery, or maternity units during a 3-week period. Genetic fingerprinting showed that the outbreak strain was closely related to the USA 400 strain that includes the midwestern strain MW2. All isolates contained the staphylococcal chromosome cassette mec type IV. Genes for Panton-Valentine leukocidin and staphylococcal enterotoxin K were detected in all isolates, and most contained other enterotoxin genes. Testing of nearly 2,000 MRSA isolates collected during citywide surveillance studies from 1999 to 2003 showed that approximate, equals 1% were genetically related to MW2. CA-MRSA strain MW2 has been present in this region at least since 1999. This study documents the spread of this strain among healthy newborns at 1 hospital.Entities:
Mesh:
Year: 2005 PMID: 15963273 PMCID: PMC3367583 DOI: 10.3201/eid1106.040885
Source DB: PubMed Journal: Emerg Infect Dis ISSN: 1080-6040 Impact factor: 6.883
Clinical information for patients with methicillin-resistant Staphylococcus aureus infection during the outbreak period
| Patient | Age at onset | Sex | Strain | Infection type | Initial therapy | Definitive therapy |
|---|---|---|---|---|---|---|
| P1, newborn | 8 d | F | USA 400 | Preseptal cellulitis | Nafcillin, cefotaxime | Topical gentamicin |
| P2, newborn | 13 d | F | USA 400 | Omphalitis, otitis externa | Ampicillin, cefotaxime | Topical mupirocin |
| P3, mother | 33 y | F | USA 400 | Breast abscess | Cefazolin | Surgical drainage, vancomycin, topical mupirocin |
| P4, newborn | 2 d | M | USA 400 | Omphalitis, pustulosis | Nafcillin Gentamicin | Gentamicin, topical mupirocin |
| P5, newborn | 4 d | M | USA 400 | Pustulosis | Cephalexin | Topical bacitracin |
| P6, newborn | 2 d | M | USA 400 | Pustulosis | None | Local wound care |
| P7, newborn | 1 d | F | USA 400 | Pustulosis, mastitis | Topical mupirocin | Vancomycin |
| P8, mother | 24 y | F | Unique | Peripheral IV catheter site | Cefazolin | Trimethoprim-sulfamethoxazole, catheter removal |
Figure 1Time course of hospitalizations and onset of methicillin-resistant Stpahylococcus aureus illness during the outbreak at Hospital A. Solid bars represent period of hospitalization; arrows represent onset of clinical infection.
Figure 2A) Ribotype and B) pulsed-field gel electrophoresis patterns of 8 clinical isolates of methicillin-resistant Staphylococcus aureus. Outbreak-related isolates P1–P7 are closely related to MW2. Clinical isolate P8 and the 3 isolates from healthcare workers (S1–S3) are unrelated to the outbreak strain.
Susceptibility data on Staphylococcus aureus isolates collected from 11 to 15 hospitals in 1999, 2001, and 2003*
| 1999 (N = 567) | 2001 (N = 772) | 2003 (N = 588) | |
|---|---|---|---|
| % MRSA | 36 | 46 | 52 |
| Antimicrobial agent (% susceptible) | |||
| Azithromycin | 14 | 5 | 5 |
| Clindamycin | 18 | 15 | 20 |
| Vancomycin | 100 | 100 | 100 |
| Daptomycin | ND | 100 | 100 |
| Tigecycline | ND | ND | 100 |
| Minocycline | 98 | ND | 98 |
| Linezolid | 100 | ND | 100 |
| Rifampin | 88 | 92 | 95 |
| Imipenem | 37 | 49 | 56 |
| Ciprofloxacin | 10 | 8 | 7 |
| Trimethoprim-sulfamethoxazole | 75 | 80 | 89 |
*MRSA, methicillin-resistant Staphylococcus aureus; ND, not done.